What is claimed is:

1. A therapeutically active composition comprising an admixture of *Crinum latifolium L*. dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the *Crinum latifolium L*. dry extract to EGCG in the composition ranges from 1:10 wt/wt to 100:1 wt/wt.

2. A therapeutically active composition comprising isolated Crila® composition 1 to 20, of Table 1.

3. The therapeutically active composition comprising isolated Crila® composition of Claim 2 selected from the group consisting of:

Crila® composition 1 comprising the components **A, B**, **C**, **D**, **E**, **F**, **G**, **H**, **I**, **J** and **K**;

Crila® composition 2 comprising the components **A** and **B**;

Crila® composition 3 comprising the components **A**, **B** and **C**;

Crila® composition 4 comprising the components **A**, **B**, **C** and **D**;

Crila® composition 5 comprising the components **A** and **C**;

Crila® composition 6 comprising the components **A**, **C** and **D**;

Crila® composition 7 comprising the components **A**, **B**, **G** and **H**;

Crila® composition 8 comprising the components **D**, **E**, **F**, **G** and **H**;

Crila® composition 9 comprising the components **A**, **D**, **E**, **F**, **G** and **H**;

Crila® composition 10 comprising the components **A**, **F**, **G** and **H**;

Crila® composition 11 comprising the components **A**, **B**, **C**, **I**, **J** and **K**;

Crila® composition 12 comprising the components **C**, **D**, **E** and **F**;

Crila® composition 13 comprising the components **C**, **D**, **E**, **F**, **G**, **H** and **I**;

Crila® composition 14 comprising the components **D**, **E** and **F**;

Crila® composition 15 comprising the components **D**, **E**, **F**, **G** and **H**;

Crila® composition 16 comprising the components **A**, **D**, **E** and **F**;

Crila® composition 17 comprising the components **C**, **D**, **G**, **H** and **I**;

o

Crila® composition 18 comprising the components **D**, **E**, **F**, **J** and **K**;

Crila® composition 19 comprising the components **A**, **B**, **C**, **D**, **E**, **F** and **G**; and

Crila® composition 20 comprising the components **E**, **F**, **G** and **H**.

4. The composition of Claim 1, wherein the ratio of the Crila® to EGCG in the composition ranges from 1:1 wt/wt to 10:1 wt/wt.

5. The composition of Claim 4, wherein the ratio of the Crila® to EGCG in the composition ranges from 1:1 wt/wt to 5:1 wt/wt.

6. The composition of Claim 4, wherein the ratio of the Crila® to EGCG in the composition ranges from 4.0:1 wt/wt to 5.5:1 wt/wt.

7. The composition of any one of Claim 1 and Claims 4 to 6, wherein the Crila® and EGCG are formulated as a dry powder.

8. The composition of Claim 7, wherein the Crila® and EGCG is formulated in a capsule formulation or capsule dosage form.

9. A pharmaceutical composition comprising a therapeutically active composition comprising an admixture of *Crinum latifolium L*. dry extract (Crila®) and epigallocatechin gallate (EGCG) of any one of Claim 1 and Claims 4 to 6;

and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of intramural or subserosal fibroids (uterine leiomyomas).

10. Use of a therapeutically active composition in the manufacture of a medicament for at least one of treating, preventing, slowing the progression of, and reversing one or more symptoms of intramural or subserosal fibroids (uterine leiomyomas) in a subject, or at risk of having one of intramural or subserosal fibroids in a subject in need thereof, said composition comprising an admixture of *Crinum latifolium L.* dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the *Crinum latifolium L.* dry extract to EGCG in the composition ranges from 1:10 wt/wt to 100:1 wt/wt, wherein the medicament is to be administered to the subject per day, to prevent, slow the progression of, and/or arrest intramural or subserosal fibroids.

o

11. The use according to Claim 10, wherein the ratio of the Crila® to EGCG in the composition ranges from 1:1 wt/wt to 10:1 wt/wt.

12. Use of a therapeutically active composition in the manufacture of a medicament for at least one of treating, preventing, slowing the progression of, and reversing one or more symptoms of intramural or subserosal fibroids (uterine leiomyomas) in a subject, or at risk of having one of intramural or subserosal fibroids in a subject in need thereof, said composition comprising isolated Crila® composition, wherein the isolated Crila® composition is selected from the group consisting of:

Crila® composition 1 comprising the components **A, B, C, D, E, F, G, H, I, J and K**;

Crila® composition 2 comprising the components **A** and **B**;

Crila® composition 3 comprising the components **A**, **B** and **C**;

Crila® composition 4 comprising the components **A**, **B**, **C** and **D**;

Crila® composition 5 comprising the components **A** and **C**;

Crila® composition 6 comprising the components **A**, **C** and **D**;

Crila® composition 7 comprising the components **A**, **B**, **G** and **H**;

Crila® composition 8 comprising the components **D**, **E**, **F**, **G** and **H**;

Crila® composition 9 comprising the components **A**, **D**, **E**, **F**, **G** and **H**;

Crila® composition 10 comprising the components **A**, **F**, **G** and **H**;

Crila® composition 11 comprising the components **A**, **B**, **C**, **I**, **J** and **K**;

Crila® composition 12 comprising the components **C**, **D**, **E** and **F**;

Crila® composition 13 comprising the components **C**, **D**, **E**, **F**, **G**, **H** and **I**;

Crila® composition 14 comprising the components **D**, **E** and **F**;

Crila® composition 15 comprising the components **D**, **E**, **F**, **G** and **H**;

Crila® composition 16 comprising the components **A**, **D**, **E** and **F**;

Crila® composition 17 comprising the components **C**, **D**, **G**, **H** and **I**;

Crila® composition 18 comprising the components **D**, **E**, **F**, **J** and **K**;

Crila® composition 19 comprising the components **A**, **B**, **C**, **D**, **E**, **F** and **G**; and

Crila® composition 20 comprising the components **E**, **F**, **G** and **H**,

wherein the medicament is to be administered to the subject to prevent, slow the progression of, and/or arrest intramural or subserosal fibroids.

13. The use according to Claims 10 to 12, wherein the Crila® and EGCG, or the Crila® composition is formulated in a capsule formulation or capsule dosage form.

o

14. Use of a therapeutically active composition or the isolated Crila® composition of Claim 2, in the manufacture of a medicament for treating intramural or subserosal fibroids in a subject in need thereof, said therapeutically active composition comprising an admixture of *Crinum latifolium L.* dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the *Crinum latifolium L.* dry extract to EGCG in the therapeutically active composition ranges from 1:10 wt/wt to 100:1 wt/wt, wherein the medicament is to be administered to the subject.

15. The use according to Claim 14, wherein the administration of the therapeutically active composition result in a significant modulation of the signaling pathways involved in cell proliferation, inflammation, apoptosis and metastasis resulting in at least one of the reduction and elimination of the growth of intramural or subserosal fibroids in the subject.

16. Use of a therapeutically active composition in the manufacture of a medicament for at least one of treating, preventing, slowing the progression of, and reversing one or more symptoms of intramural or subserosal fibroids (uterine leiomyomas) in a subject, or at risk of having one of intramural or subserosal fibroids in a subject in need thereof, said composition comprising *Crinum latifolium L.* dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the *Crinum latifolium L.* dry extract to EGCG in the composition ranges from 1:10 wt/wt to 100:1 wt/wt, wherein the medicament is to be administered to the subject.

17. The use according to any one of Claims 14 to 16, wherein the administration of *Crinum latifolium L.* dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the *Crinum latifolium L.* dry extract to EGCG in the composition ranges from 1:10 wt/wt to 100:1 wt/wt, and wherein the administration is a concomitant administration of Crila® and EGCG.

18. The use according to any one of Claims 12 to 17, wherein the administration of Crila® is 920 mgs, two capsules BID equivalent to 3680 mgs per day for 90 days, and the administration of EGCG 400 mgs, one capsule BID equivalent to 800 mgs per day for 90 days.

19. The use according to any one of Claims 12 to 17, wherein the dose of Crila® administered is between 50 mg to 5,000 mg per day, and the dose of EGCG administered is

o

between 50 mg to 1,000 mg per day, wherein the composition comprising Crila® and EGCG is administered daily for at least 30 days, 60 days, 90 days, or 120 days.

20. Use of a therapeutically effective amount of a composition in the manufacture of a medicament for the treatment of cancer in a patient, said composition comprising isolated Crila® composition, wherein the isolated Crila® composition is selected from the group consisting of:

Crila® composition 1 comprising the components **A**, **B**, **C**, **D**, **E**, **F**, **G**, **H**, **I**, **J** and **K**;
Crila® composition 2 comprising the components **A** and **B**;
Crila® composition 3 comprising the components **A**, **B** and **C**;
Crila® composition 4 comprising the components **A**, **B**, **C** and **D**;
Crila® composition 5 comprising the components **A** and **C**;
Crila® composition 6 comprising the components **A**, **C** and **D**;
Crila® composition 7 comprising the components **A**, **B**, **G** and **H**;
Crila® composition 8 comprising the components **D**, **E**, **F**, **G** and **H**;
Crila® composition 9 comprising the components **A**, **D**, **E**, **F**, **G** and **H**;
Crila® composition 10 comprising the components **A**, **F**, **G** and **H**;
Crila® composition 11 comprising the components **A**, **B**, **C**, **I**, **J** and **K**;
Crila® composition 12 comprising the components **C**, **D**, **E** and **F**;
Crila® composition 13 comprising the components **C**, **D**, **E**, **F**, **G**, **H** and **I**;
Crila® composition 14 comprising the components **D**, **E** and **F**;
Crila® composition 15 comprising the components **D**, **E**, **F**, **G** and **H**;
Crila® composition 16 comprising the components **A**, **D**, **E** and **F**;
Crila® composition 17 comprising the components **C**, **D**, **G**, **H** and **I**;
Crila® composition 18 comprising the components **D**, **E**, **F**, **J** and **K**;
Crila® composition 19 comprising the components **A**, **B**, **C**, **D**, **E**, **F** and **G**; and
Crila® composition 20 comprising the components **E**, **F**, **G** and **H**,
wherein the medicament is to be administered to a patient in need of such treatment.

21. The use according to Claim 20, wherein the cancer is selected from the group consisting of leukemia, neuroblastoma, glioblastoma, cervical, colorectal, pancreatic, renal and melanoma.

o

22. The use according to Claim 20, wherein the cancer is selected from the group consisting of lung, breast, prostate, ovarian and head and neck.

o